Moon Dain, Tae Nara, Park Yunji, Lee Seung-Woo, Kim Dae Hee
Department of Life Sciences, Pohang University of Science and Technology (POSTECH), Pohang 37673, Korea.
Global/Gangwon Innovative Biologics Regional Leading Research Center (GIB-RLRC), Kangwon National University, Chuncheon 24341, Korea.
Immune Netw. 2022 Feb 14;22(1):e4. doi: 10.4110/in.2022.22.e4. eCollection 2022 Feb.
In the era of immunotherapeutic control of cancers, many advances in biotechnology, especially in Ab engineering, have provided multiple new candidates as therapeutic immuno-oncology modalities. Bispecific Abs (BsAbs) that recognize 2 different antigens in one molecule are promising drug candidates and have inspired an upsurge in research in both academia and the pharmaceutical industry. Among several BsAbs, T cell engaging BsAb (TCEB), a new class of therapeutic agents designed to simultaneously bind to T cells and tumor cells via tumor cell specific antigens in immunotherapy, is the most promising BsAb. Herein, we are providing an overview of the current status of the development of TCEBs. The diverse formats and characteristics of TCEBs, in addition to the functional mechanisms of BsAbs are discussed. Several aspects of a new TCEB-Blinatumomab-are reviewed, including the current clinical data, challenges of patient treatment, drawbacks regarding toxicities, and resistance of TCEB therapy. Development of the next generation of TCEBs is also discussed in addition to the comparison of TCEB with current chimeric antigen receptor-T therapy.
在癌症免疫治疗控制的时代，生物技术的许多进展，特别是在抗体工程方面，为免疫肿瘤治疗方式提供了多种新的候选药物。双特异性抗体（BsAbs）在一个分子中识别两种不同抗原，是很有前景的候选药物，并激发了学术界和制药行业的研究热潮。在几种BsAbs中，T细胞接合双特异性抗体（TCEB）是最有前景的BsAb，它是一类新型治疗剂，旨在通过免疫疗法中的肿瘤细胞特异性抗原同时结合T细胞和肿瘤细胞。在此，我们概述了TCEBs的发展现状。除了BsAbs的功能机制外，还讨论了TCEBs的不同形式和特点。对一种新的TCEB——blinatumomab的几个方面进行了综述，包括当前的临床数据、患者治疗的挑战、毒性方面的缺点以及TCEB治疗的耐药性。除了将TCEB与当前的嵌合抗原受体-T疗法进行比较外，还讨论了下一代TCEBs的开发。
